CTOs on the Move

Novavax

www.novavax.com

 
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company’s proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.novavax.com
  • 20 Firstfield Road
    Gaithersburg, MD USA 20878
  • Phone: 240.268.2000

Executives

Name Title Contact Details
Donald Medlin
 Associate Director Security Services Profile
Raj Sharma
 Chief Information Security Officer Profile
Biegie Lee
 Senior Vice President and. Chief Information Officer Profile

Funding

Novavax raised $384M on 05/11/2020
Novavax raised $200M on 06/15/2020
Novavax raised $1.6B on 07/07/2020

Similar Companies

Emergent BioSolutions

Emergent BioSolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.

Alfa Wassermann

Alfa Wassermann, Inc. is a West Caldwell, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gel-Del

Gel-Del is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioTime

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime`s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime`s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.

OraPharma , Inc.

OraPharma , Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.